Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Alto Neuroscience, Inc.NYSE: ANRO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.84M rose 20.0% year over year, ahead of the -3.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 35.3% from the prior quarter. Over 3 fiscal years it compounded at +59.0% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -4.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.84M+35.3% QoQ
- Last fiscal yearDec 2025
- $20.75M-4.0% YoY
- LTMMar 2026
- $21.89M-3.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 20.75M USD
- Year-over-year change
- -4.0%
- 4-year CAGR
- +53.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.75M | -4.0% |
| FY2024 | 2024-12-31 | 21.61M | +187.5% |
| FY2023 | 2023-12-31 | 7.52M | +45.6% |
| FY2022 | 2022-12-31 | 5.16M | +37.6% |
| FY2021 | 2021-12-31 | 3.75M | — |
Selling, General & Admin vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.6% is the 8th highest of 10, against a peer median of +13.5%.
- Over three fiscal years its annual growth of +59.0% compares with a peer median of +4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.14T USD | +9732467.6% | -14.5% | — | |
| LTM Mar 2026 | $99.54M USD | -33.2% | -27.7% | 46.3% | |
| LTM Mar 2026 | $38.19M USD | +65.9% | +17.2% | — | |
| LTM Mar 2026 | $30.49M USD | -15.8% | +18.8% | 793.5% | |
| LTM Mar 2026 | $23.59M USD | — | +2.2% | 2560.2% | |
| LTM Mar 2026 | $21.89M USD | -3.6% | +59.0% | — | |
| LTM Mar 2026 | $19.82M USD | +7.4% | +14.2% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $17.4M USD | +18.2% | +41.6% | — |
| LTM Mar 2026 | CHF 11.38M CHF | +4.4% | +6.7% | 307.5% | |
| LTM Mar 2026 | $10.42M USD | +13.5% | -3.1% | — | |
| LTM Mar 2026 | $9.18M USD | +20.3% | -1.1% | 13.5% | |
| Peer median (excluding ANRO) | — | +13.5% | +4.5% | 307.5% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 210K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 145K | 342K | 0 | 502K | 661K |
| Gross Profit | 65K | (342K) | 0 | (502K) | (661K) |
| Gross Margin | 31.0% | — | — | — | — |
| Research & Development | 8.37M | 23.69M | 30.29M | 47M | 45.62M |
| Selling, General & Admin | 3.75M | 5.16M | 7.52M | 21.61M | 20.75M |
| Operating Expenses | 12.12M | 28.85M | 37.81M | 68.11M | 65.7M |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| EBITDA | (9.04M) | (27.37M) | (34.56M) | (62.3M) | (60.11M) |
| EBITDA Margin | -4305.7% | — | — | — | — |
| Operating Income | (12.06M) | (29.19M) | (37.81M) | (68.61M) | (66.36M) |
| Operating Margin | -5741.0% | — | — | — | — |
| Interest Income | 2K | 114K | 2.35M | 8.85M | 6.6M |
| Interest Expense | 0 | 0 | 1.37M | (1.38M) | 2.47M |
| Other Income / Expenses | 2.87M | 1.48M | 1.5M | 7.18M | 3.13M |
| Income Before Tax | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Pre-Tax Margin | -4374.8% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Net Margin | -4374.8% | — | — | — | — |
| EPS (Basic) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| EPS (Diluted) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| Weighted Avg Shares | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
| Weighted Avg Shares (Diluted) | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.